44 BIOTECHNOLOGY
amine) anion-exchange membrane from Sartorius Stedim Biotech overcomes this limitation and binds contaminants at high conductivities under high-salt conditions at up to 20mS/cm. Te salt-tolerant anion exchanger can directly process cation-exchange pools without further dilution. Buffer consumption and buffer tank investments can be reduced.
Sartobind pico with 0.08ml is the latest member of the Sartobind STIC family with nano, 5-in, 10-in, 30-in and mega capsules. Since all devices are used for flow-through polishing, a 4mm bed height is kept constant to scale to larger devices up to 1.6 litres. Te small membrane volume of 0.08ml reduces material consumption during testing and virus spiking studies to save cost during the initial development phases (Fig. 2).
All membrane adsorber capsules are ‘plug and play’ devices and can be used like filters. As the materials are disposed of after a single use, this saves validation costs.
New from GE Healthcare Life Sciences are Streptavidin Mag Sepharose magnetic beads. Tese have a high binding capacity for purification of biotinylated biomolecules and enrichment of target proteins. Te magnetic beads help simplify handling, and rapid capture is facilitated by magnetic devices while delivering scalability and high yield, from low microlitre to high millilitre scale sample volumes.
Streptavidin Mag Sepharose beads support reliable sample preparation for downstream analysis and have a more than 400-fold enrichment factor to promote an increased
identification rate of target proteins. Te magnetic beads are hydrophilic with a high density to ensure the beads do not aggregate. Tey are available in two pack sizes, 2 x 1mL and 5 x 1mL. In addition, the MagRack Maxi has been launched to facilitate handling and to support sample capacities of up to 50mL.
From the same company, the rProtein A GraviTrap, Protein G GraviTrap, and rProtein A/ Protein G GraviTrap gravity-flow columns enable single-step manual purification of monoclonal and polyclonal antibodies from various species in milligram scale. Te purification run time is approximately 30 minutes (dependent on sample).
Designed for small-scale antibody purification, the product package contains everything needed for manual purification, as it converts into a column stand (Workmate) with a plastic tray to collect liquid waste. Each pack contains ten pre-packed columns to facilitate multiple samples to be purified simultaneously, using a gravity format. Columns contain 1 mL bed volume and can bind milligram amounts of antibodies. Te columns are reusable up to five times depending on the sample.
Fig. 2. The small membrane volume reduces material consumption during testing and virus spiking, so reducing costs.
B
Bio-Rad purchases QuantaLife
io-Rad Laboratories has purchased QuantaLife for US$162m (€124m) in cash plus potential future milestone payments. QuantaLife has
developed an innovative digital polymerase chain reaction (PCR) system that provides quantification of target molecules with unprecedented precision and sensitivity. This next generation PCR technology builds on the well-established method of amplifying DNA that is used in research laboratories around the world. Digital PCR provides researchers with a new tool for the
www.scientistlive.com
For its part, Phenomenex has introduced the Phenex-GF/NY dual- membrane syringe filter for viscous, particulate-laden samples. Te
detection of rare mutations including distinguishing rare sequences in tumours, precise measurement of copy number variation, and absolute quantification of gene expression. “We are impressed with QuantaLife’s digital
PCR technology and believe it will complement Bio- Rad’s existing amplification business,” said Norman Schwartz, Bio-Rad president and ceo. “This elegant solution expands the current state of the art methods of quantitative PCR (qPCR), and we look forward to its adoption in life science research.” Based in Pleasanton, California, QuantaLife was a privately-held life sciences company that provides
new filter incorporates a glass layer, through which the sample passes first for elimination of heavy particulates, increasing the effectiveness of the second, nylon fibre membrane. By removing particulates from the sample, the syringe filter prevents build-up and blockage of chromatography columns and frits while minimising wear and tear on injection valves. Proper sample filtration can ultimately reduce system downtime and component replacement.
Ideal for any applications with highly viscous or heavily particulate-laden samples, such as foods, biological fluids, soil and fermentation broths, Phenex-GF/NY performs at higher capacity than nylon-only filters, and requires less hand pressure to filter the sample. Phenex syringe filters are optimised for superior flow rates and high throughput.
Finally, designed to meet the pressure-flow requirements of commercial-scale bioprocesses, Nuvia Q high-capacity anion exchange media from Bio-Rad exhibits a binding capacity of greater than 170mg/mL at a flow rate of 300cm/hr. By maintaining high binding capacity even at fast flow rates, Nuvia Q can help improve productivity while reducing cycle time for downstream biotherapeutics purification. Moreover, less media is required for a given unit operation. Nuvia Q targets the purification of mAbs, recombinant proteins, and vaccines.
advanced genetic analysis systems for research. QuantaLife has commercialised the droplet digital (ddPCR) system, the most accurate genetic analysis platform available today. The system is the first cost- effective, high-resolution platform available for the validation of next-generation sequencing discoveries. The company says it is easy to use, easy to automate, and easy to integrate into existing workflows in both life science and clinical research labs. With the ddPCR system, researchers can explore complex genetic landscapes in high-definition, discover new disease associations, and define a new category of improved molecular diagnostic tests.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52